文献速递肿瘤 PET/CT核素与放射性配体治疗

雄激素受体阻断上调肿瘤PSMA表达范式的新见解:恩扎卢胺可上调去势抵抗性前列腺癌的PSMA表达,即使患者既往接受恩扎卢胺治疗后已进展

New insights in the paradigm of upregulation of tumoral PSMA expression by androgen receptor blockade: Enzalutamide induces PSMA upregulation in castration-resistant prostate cancer even in patients having previously progressed on enzalutamide.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2020-01-03

本研究纳入10例计划接受PSMA放射性配体治疗的晚期转移性去势抵抗性前列腺癌(mCRPC)患者,在口服恩扎卢胺160 mg/天平均11.8天前后行68Ga-PSMA-11 PET/CT,以总PSMA肿瘤负荷定量比较。结果显示全身TLP-肝比值、TLP-腮腺比值和TLP-肾比值分别平均(中位)升高49.3%(38.8%)、45.1%(23.5%)和54.9%(37.6%),均具统计学显著性,而PSA值无显著变化;10例中7例既往恩扎卢胺治疗后进展。作者认为恩扎卢胺可考虑作为增强PSMA放射性配体治疗的预处理药物,该观察值得在前瞻性研究中评估。

要点

  • 恩扎卢胺160 mg/天平均11.8天后,TLP-肝比值平均(中位)升高49.3%(38.8%),P=0.002。
  • TLP-腮腺比值与TLP-肾比值分别平均(中位)升高45.1%(23.5%)与54.9%(37.6%),P均为0.014。
  • 同期PSA值无显著变化(P=0.846),短期未见副作用;10例中7例既往恩扎卢胺治疗失败。

核心结论

  • 作者认为恩扎卢胺可考虑作为增强PSMA放射性配体治疗的预处理药物,可能使mCRPC的PSMA表达提高约50%。
  • 该效应在既往因mCRPC进展而恩扎卢胺治疗失败的患者中仍可观察到。
  • 作者指出该观察值得在前瞻性研究中评估。

研究设计与样本

  • 10例计划接受PSMA放射性配体治疗的晚期mCRPC患者,在口服恩扎卢胺160 mg/天平均11.8天前后行68Ga-PSMA-11 PET/CT。
  • 采用总PSMA肿瘤负荷定量比较影像结果,评估全身总病灶PSMA(TLP,定义为SUVmean×肿瘤体积)及TLP-肝比值(TLP-LR)、TLP-腮腺比值(TLP-PR)、TLP-肾比值(TLP-KR)。
  • 10例中7例既往接受过恩扎卢胺治疗并最终进展,正式归类为治疗失败。

主要发现

  • 队列TLP-LR平均(中位)升高49.3%(38.8%),差异有统计学显著性(P=0.002)。
  • 队列TLP-PR平均(中位)升高45.1%(23.5%),差异有统计学显著性(P=0.014)。
  • 队列TLP-KR平均(中位)升高54.9%(37.6%),差异有统计学显著性(P=0.014)。
  • PSA值无显著变化(P=0.846)。
  • 短期未见副作用。

关键数值与推荐

  • 恩扎卢胺给药方案为160 mg/天口服,平均用药11.8天后复查68Ga-PSMA-11 PET/CT。
  • TLP定义为SUVmean×肿瘤体积,并计算TLP-LR、TLP-PR和TLP-KR。

临床怎么用

  • 作者认为恩扎卢胺可考虑作为增强PSMA放射性配体治疗的预处理药物。
  • 作者指出该观察值得在前瞻性研究中评估。

局限性

  • 作者指出该观察值得在前瞻性研究中评估。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: There is preliminary evidence for prostate-specific membrane antigen (PSMA) upregulation effects of androgen receptor blockade in prostate cancer. In an attempt to find the best condition for PSMA radioligand therapy in metastatic castration-resistant prostate cancer (mCRPC) patients, we evaluated the effect of oral enzalutamide in patients, predominantly having previously progressed on enzalutamide treatment. METHODS: Ten patients with advanced mCRPC scheduled for PSMA radioligand therapy were examined with 68Ga-PSMA-11 PET/CT before and after a mean of 11.8 days of enzalutamide 160 mg/day. Imaging results were compared using total PSMA tumor burden quantification. We assessed whole-body total lesion PSMA (TLP), defined as SUVmean × tumor volume and calculated TLP-to-liver ratio (TLP-LR), TLP-to-parotid gland ratio (TLP-PR), and TLP-to-kidney ratio (TLP-KR). RESULTS: The mean (median) increase of TLP-LR, TLP-PR, and TLP-KR in the cohort was 49.3% (38.8%), 45.1% (23.5%), and 54.9% (37.6%), respectively. These increases were statistically significant (p = 0.002, p = 0.014, and p = 0.014), while PSA values did not change significantly (p = 0.846). Seven of the 10 patients had previously undergone enzalutamide treatment with eventual progression, formally classified as treatment failure. No side effects were noted in the short term. CONCLUSIONS: Our results suggest that enzalutamide could be considered as a PSMA radioligand treatment enhancing primer medication, which may increase PSMA expression by a dimension of 50% in mCRPC. The effect was shown even in patients having previously failed enzalutamide treatment for arrest of progression in the mCRPC setting. Our observation deserves evaluation in a prospective setting.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Rosar F, Dewes S, Ries M, et al. New insights in the paradigm of upregulation of tumoral PSMA expression by androgen receptor blockade: Enzalutamide induces PSMA upregulation in castration-resistant prostate cancer even in patients having previously progressed on enzalutamide. Eur J Nucl Med Mol Imaging. 2020. PMID: 31901103. doi:10.1007/s00259-019-04674-0

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。